Rare Bleeding Disorders: Overview of Clinical Assessment and Diagnosis
In the Monday afternoon session entitled Rare Bleeding Disorders, Flora Peyvandi gives an overview of RBDs in Europe and discusses current technical limitations in laboratory testing, presents current treatments, and also discusses novel treatment strategies.
Gene Therapy for Haemophilia: What, Why, How, When, Who, and Where?
In the Sunday afternoon session entitled Gene Therapy: Back to Basics, Glenn Pierce explains the state of the art and the future prospects of gene therapy, gene editing, and cell therapy, in the context of hemophilia.
Gene Therapy: Past, Present, and Future
The second activity in the Clinical Advances in Gene Therapy for Hemophilia CME curriculum, Gene Therapy: Past, Present, and Future, is a round table video discussion of the evolution of gene therapy in hemophilia. Watch three experts reflect on the development, ongoing research, and current and future uses of gene therapy in hemophilia. A transcript […]
Congenital Fibrinogen Disorders: Clinical features and management
In the Wednesday morning session on rare and ultra-rare bleeding disorders, Philippe de Moerloose disscusses the issues of congenital fibrinogen disorders.
Factor FXIII Deficiency
In the Wednesday morning session on rare and ultra-rare bleeding disorders, Diane Nugent presents work on FXIII deficiency.
Health Technology Assessment: Introduction, American perspective, and European perspective
In the Tuesday afternon session on Health Technology Assessments (HTA), Mark Skinner introduces the topic and then Cliff Goodman and Chris Henshall alternate to present the American and European perspectives, respectively.
The Challenge of Evidence Generation
In the Tuesday morning WFH session on global surveillance and collaboration, Glenn Pierce, explores the challenges of evidence generation.
Essential Medicines List, Orphan Drugs, and Paid Plasma
In the Tuesday morning WFH session on global surveillance and collaboration, Brian O’Mahony, provides his vision for the role of the WFH in ensuring adequate access to a safe supply of hemophilia treatment.
Blood Safety and Donor Deferrals: The history and ongoing risk evaluation
In the Tuesday morning WFH session on global surveillance and collaboration, David Page, discusses donor deferrals, issues of blood safety and the role of the WFH.
Medical Plenary: Hemophilia treatment in 2030
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.
Ageing with hemophilia: Dental issues
In the Thursday morning session entitled Ageing with Hemophilia: Issues and Challenges Through Different Life Stages, Andrew Brewer presents his experiences working as a dentist with people with hemophilia of all ages. This talk was part of the Panel Discussion session: Ageing with Hemophilia: Issues & challenges through different life stages. See below for other […]
Porcine Factor VIII
In the Monday afternoon session on alternative therapies in the management of inhibitors, Rebecca Kruse-Jarres discusses the latest developments in the use of porcine factor VIII.